Recent Comments

Comment RSS

Doxorubicin News and Research RSS Feed - Doxorubicin News and Research

Doxorubicin hydrochloride is approved for use with other drugs as adjuvant therapy for breast cancer that has spread to the lymph nodes, including cancer that is HER-2 positive or has spread after surgery.

In addition to the uses that have been approved by the FDA, doxorubicin hydrochloride is sometimes used alone or with other drugs to treat other types of cancer. The drug continues to be studied in the treatment of many types of cancer.

Brentuximab vedotin-chemotherapy combination clinical trial for Hodgkin lymphoma announced

4. February 2010 01:12
Seattle Genetics, Inc. and Millennium Pharmaceuticals, Inc.: The Takeda Oncology Company today announced that they have initiated a phase I clinical trial of brentuximab vedotin (SGN-35) in combination with chemotherapy for the treatment of newly diagnosed Hodgkin lymphoma patients. Brentuximab vedotin is an antibody-drug conjugate (ADC) that is also in single-agent clinical trials, including a pivotal trial for relapsed and refractory Hodgkin lymphoma and a phase II trial for systemic anaplastic large cell lymphoma. [More]

Posted in: Drug Trial News | Medical Condition News

Tags: , , , , , , , , , , , , , , ,

Permalink | Comments (0)

Spectrum Pharmaceuticals signs co-development and commercialization agreement with TopoTarget A/S

2. February 2010 06:40
Spectrum Pharmaceuticals, a commercial-stage biotechnology company with a primary focus in oncology, today announced that it has entered into a co-development and commercialization agreement with TopoTarget A/S for Belinostat, a novel histone deacetylase (HDAC) inhibitor. [More]

Posted in: Business / Finance | Pharmaceutical News

Tags: , , , , , , , , , , , , ,

Permalink | Comments (0)

NCCN updates the NCCN Clinical Practice Guidelines for Oncology for Ovarian Cancer

27. January 2010 02:51
The National Comprehensive Cancer Network (NCCN) recently updated the NCCN Clinical Practice Guidelines for Oncology™ for Ovarian Cancer to reflect the addition of two preferred combination regimens for a specific cohort of patients based on data from recent clinical research studies. [More]

Posted in: Women's Health News

Tags: , , , , , , , ,

Permalink | Comments (0)

Researchers identify new gene signature that predicts cancer recurrence in certain breast tumors

24. January 2010 23:43
Researchers at Dana-Farber Cancer Institute have discovered a gene activity signature that predicts a high risk of cancer recurrence in certain breast tumors that have been treated with commonly used chemotherapy drugs. [More]

Posted in: Medical Science News | Medical Condition News

Tags: , , , , , , , , , , , , , , , ,

Permalink | Comments (0)

CytRx announces its plans to advance multiple oncology development programs in 2010

22. January 2010 02:17
CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced its plans for 2010 aimed at advancing the clinical development of its high-value drug development pipeline and enhancing shareholder value. [More]

Posted in: Business / Finance | Pharmaceutical News

Tags: , , , , , , , , , , , , , , , , ,

Permalink | Comments (0)

FDA issues Fast Track Designation to Sopherion Therapeutics' Myocet

7. January 2010 07:47
Sopherion Therapeutics, LLC, a biopharmaceutical company focused on the development and commercialization of anti-cancer therapies, announced today that it has received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for nonpegylated liposomal doxorubicin (Myocet(TM)) for first-line therapy of HER2 positive metastatic breast cancer. [More]

Posted in: Women's Health News | Pharmaceutical News

Tags: , , , , , , , ,

Permalink | Comments (0)

Tumor Biology Center to initiate Phase 2 clinical trial with CytRx’s INNO-206

6. January 2010 23:41
CytRx Corporation, a biopharmaceutical company, today announced that the Tumor Biology Center, Freiburg, Germany, plans to initiate a Phase 2 clinical trial with CytRx’s doxorubicin prodrug INNO-206 as a treatment for patients with advanced pancreatic cancer. [More]

Posted in: Drug Trial News | Medical Condition News

Tags: , , , , , , , , ,

Permalink | Comments (0)

"Nanoworms" and doxorubicin loaded hollow nanoparticles to fight cancer

5. January 2010 03:26
A team of researchers in California and Massachusetts has developed a "cocktail" of different nanometer-sized particles that work in concert within the bloodstream to locate, adhere to and kill cancerous tumors. [More]

Posted in: Medical Science News | Medical Condition News

Tags: , , , ,

Permalink | Comments (0)

VELCADE sNDA receives FDA approval

5. January 2010 00:58
Millennium: The Takeda Oncology Company today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for VELCADE, which expands the label to include long-term (median follow-up 36.7 months) overall survival (OS) data from the landmark VISTA trial and provides specific dosing recommendations for patients with hepatic impairment. The VISTA trial examined the use of VELCADE based therapy in patients with previously untreated multiple myeloma (MM). [More]

Posted in: Medical Condition News | Pharmaceutical News

Tags: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,

Permalink | Comments (0)

A 'cocktail' to kill cancerous tumors

5. January 2010 00:00
A team of researchers in California and Massachusetts has developed a "cocktail" of different nanometer-sized particles that work in concert within the bloodstream to locate, adhere to and kill cancerous tumors. [More]

Posted in: Medical Science News | Medical Condition News

Tags: , , , ,

Permalink | Comments (0)

AEterna Zentaris terminates its agreement on cetrorelix with sanofi-aventis U.S.

18. December 2009 07:40
AEterna Zentaris Inc. (the "Company"), a global biopharmaceutical company focused on oncology and endocrine therapy, today announced the termination of its agreement with sanofi-aventis U.S. ( SNY) dated March 5, 2009 for the development, commercialization and licensing of cetrorelix in benign prostatic hyperplasia (BPH) for the U.S. market, following the Company's announcement last week of the results for its European Phase 3 study for cetrorelix in BPH. [More]

Posted in: Business / Finance | Pharmaceutical News

Tags: , , , , , , , , , ,

Permalink | Comments (0)

Four commonly used chemotherapy drugs disrupt birth of new brain cells, shows study

18. December 2009 01:57
Researchers have developed a novel animal model showing that four commonly used chemotherapy drugs disrupt the birth of new brain cells, and that the condition could be partially reversed with the growth factor IGF-1. [More]

Posted in: Medical Science News | Medical Condition News | Pharmaceutical News

Tags: , , , , , , , , , , , , , , , , , , , , , , , ,

Permalink | Comments (0)

INS cites FDA-approved Totect antidote for anthracycline extravasations

15. December 2009 04:03
The third edition of Infusion Nursing: An Evidence-Based Approach, published by the Infusion Nurses Society (INS), includes Totect(®), the only FDA-approved treatment for anthracycline extravasation. Anthracyclines are a group of chemotherapy medications including daunorubicin, doxorubicin, idarubicin and epirubicin that have been used in the treatment of various types of cancer since the early 1970s. [More]

Posted in: Medical Condition News | Pharmaceutical News

Tags: , , , , , , , , , , , , , , , , , , , ,

Permalink | Comments (0)

Researchers present new data for diagnosis and management of beast cancer

14. December 2009 04:39
As therapies for breast cancer continue to emerge, the issues of how to best monitor success and gauge prognosis remain important questions. [More]

Posted in: Medical Condition News | Women's Health News

Tags: , , , , , , , , , , , , , , , , ,

Permalink | Comments (0)

Black women with HR-positive breast cancer have worse disease-free and overall survival, shows data

14. December 2009 02:11
Black women with hormone receptor (HR)-positive breast cancer had worse disease-free and overall survival, according to data presented at the CTRC-AACR Annual San Antonio Breast Cancer Symposium, held Dec. 9-13, 2009. [More]

Posted in: Women's Health News

Tags: , , , , , ,

Permalink | Comments (0)
News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide.